Basic & Clinical Medicine ›› 2012, Vol. 32 ›› Issue (8): 921-925.
Previous Articles Next Articles
Received:
Revised:
Online:
Published:
Abstract: Objective To compare the protective effect of candoxatril combined losartan on rat myocardial hypertrophy with omapatrilat (OMA) .Methods 1mg/kg isoproterenol (ISO) was given to induce myocardial hypertrophy in Sprague-Dawley (SD) rats. Rats were randomly divided into 7 groups: control, myocardial hypertrophy, candoxatril, losartan, OMA, candoxatril + losartan(full dose and half-value dose) (all n=8). The myocardial hypertrophy index was expressed as heart weight /body weight (HW/BW),cross-sectional area (CSA), myocardial interstitial collagen volume fraction (CVF) and perivascular collagen area (PVCA); The content of plasma angiotensinⅡ(AngⅡ), atrial natriuretic peptide (ANP)and bradykinin (BK)were measured by colorimetry and radioimmunoassay;The expression of p-PI3K and p-Akt protein were detected by immunohistochemistry staining. Results 1) compared to control, ISO significantly increased heart weight index(3.64±0.30, 3.62±0.28, 4.32±0.58 respectively), CSA, CVF, PVCA (P < 0.01); candoxatril + losartan(full dose) and OMA can decreased the effect of ISO (P < 0.01) .2)ISO increased AngⅡcontent〔(741±89)ng/L,(682±66)ng/L and(479±62)ng/L respectively〕significantly and the ANP and BK level mildly compared to control. Compared to myocardial hypertrophy control group, candoxatril + losartan (full dose)and OMA both decreased plasma AngⅡ content and increased the ANP〔(117±33)μg/L,(298±91)μg/L,(288±95)μg/L respectively〕and BK〔(124±12)ng/L,(232±21) ng/L and (309±24)ng/L respectively〕level significantly (P < 0.01), but candoxatril + losartan make less BK level increase than OMA (P < 0.05).3) OMA down-regulated the expression of p-PI3K, p-Akt protein which is not better than candoxatril + losartan(full dose). Conclusion candoxatril combined losartan and OMA decrease myocardial hypertrophy in rats. There were differences in the plasma hormone level.
Key words: myocardial hypertrophy, Candoxatril, omapatrilat, losartan, bradykinin
CLC Number:
R541.2
R331.3
/ Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: https://journal11.magtechjournal.com/Jwk_jcyxylc/EN/
https://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2012/V32/I8/921